RedHill Biopharma publishes corporate presentation on GI, infectious disease, oncology pipeline
PUBT · 04/29 10:46
Share
Listen to the news
- RedHill Biopharma highlighted FY 2025 net revenues of USD 7.8 million.
- Cash balance was USD 4.1 million, with equity financing capacity of USD 31.7 million.
- Talicia, its marketed H. pylori therapy, is co-commercialized in US with Cumberland Pharmaceuticals.
- Pipeline focus includes opaganib across oncology and virus-induced ARDS, with an ongoing Phase 2 combination study in prostate cancer with Bayer’s darolutamide.
- RHB-102 is positioned for multiple GI indications, with a planned Phase 2 proof-of-concept study for GLP-1/GIP-associated GI intolerance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved